Drugdiscovery >> Drugs >> News
6047
Views
First biosimilar mAb therapy approved in Europe - drugdiscovery.com
First biosimilar mAb therapy approved in Europe - drugdiscovery.com


Hospira’s Inflectra, monoclonal antibody (mAb) therapy, a biosimilar to Remicade (infliximab), has been approved by the European Commission (EC) for the treatment of inflammatory conditions including rheumatoid arthritis , ankylosing spondylitis, Crohn's disease , ulcerative colitis, psoriatic arthritis and psoriasis.
Read More >>


Tags: Hospira, Inflectra, infliximab, Remicade, biosimilar, monoclonal antibody, inflamatory conditions, treatment, Europe - September 12, 2013
Related Articles
6980
Views
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe
The European Commission has granted marketing authorization for afatinib, used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC Read More >>

Tags: Giotrif, afatinib, locally advanced, metastatic, non-small cell lung cancer, NSCLC, EGFR mutation, EU, Europe

10294
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

6274
Views
Remicade Copies Approved in Europe Remicade Copies Approved in Europe
J&J’s Remicade, a drug for arthritis, will have cheaper versions made and sold by two other companies in Europe by 2014. Read More >>

Tags: Remicade, Arthritis, Celltrion, Hospira

11892
Views
New drug for treating myeloma approved in Europe New drug for treating myeloma approved in Europe
The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of Read More >>

Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval

8077
Views
Takeda's schizophrenia drug lurasidone approved in Swiss Takeda's schizophrenia drug lurasidone approved in Swiss
This is the first approval in Europe for lurasidone, which is already marketed as Latuda for schizophrenia and bipolar depression in the US and Canada. Read More >>

Tags: lurasidone, latuda, drug, schizophrenia, bipoloar disorder, Swiss, approval, Europe

6703
Views
Velcade approved as a first line therapy in EU Velcade approved as a first line therapy in EU
Johnson & Johnson's multiple myeloma treatment Velcade (bortezomib) has been used in advanced patients and those who were ineligible for stem cell transplantation. In the future, it will also be used Read More >>

Tags: Velcade, multiple myeloma, Johnson & Johnson, approval, EC, EU

6008
Views
The first approved treatment for negative symptoms in schizophrenia to be launched in 2016 The first approved treatment for negative symptoms in schizophrenia to be launched in 2016
Roche/Chugai's glycine transporter-1 inhibitor bitopertin is poised to be the first-in-class agent for the treatment of negative symptoms in schizophrenia. The launch in the United States and Europe ( Read More >>

Tags: bitopertin, Roche, negative symptoms in schizophrenia, schizophrenia, symptoms, negative, new drug, new therapy

2419
Views
Lojuxta authorised in Europe Lojuxta authorised in Europe
The European Commission has authorised Lojuxta, by Aegerion Pharmaceuticals, for the treatment of patients with life threatening, rare inherited disease called homozygous familial hypercholesterolaemi Read More >>

Tags: Lojuxta, Aegerion Pharmaceuticals, homozygous familial hypercholesterolaemia

4202
Views
Europe-wide cancer research collabortion is announced Europe-wide cancer research collabortion is announced
European institutions announced a collaboration for cancer research. CRT and Nuevolution says, this going to help to delvelop a trustable cure for as wide range of cancer types. Read More >>

Tags: CRT, Nuevolution, cancer, drug

3949
Views
Three New European Marketing Authorizations for Takeda Three New European Marketing Authorizations for Takeda
The European Commission has granted Marketing Authorization (MA) for Vipidia (alogliptin) for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies and for the fixed-dos Read More >>

Tags: Takeda, EMA, EC, Europe, marketing authorisation, type 2 diabetes, Vipidia, alogliptin, Vipdoment, Incresync

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013